eTNS Platform
Epilepsy
Key Facts
About NeuroSigma
NeuroSigma is a commercial-stage medical device company pioneering external trigeminal nerve stimulation (eTNS) for neuromodulation. Its flagship Monarch eTNS System holds FDA clearance for pediatric ADHD as a non-invasive, non-pharmacological treatment, representing a first-in-class device. The company is targeting large neurological markets, including epilepsy and depression, with its patented platform. Backed by clinical data from multiple trials and an extensive patent portfolio, NeuroSigma aims to provide accessible, evidence-based neurotherapeutics.
View full company profileAbout NeuroSigma
NeuroSigma is a commercial-stage medical device company pioneering external trigeminal nerve stimulation (eTNS) for neuromodulation. Its flagship Monarch eTNS System holds FDA clearance for pediatric ADHD as a non-invasive, non-pharmacological treatment, representing a first-in-class device. The company is targeting large neurological markets, including epilepsy and depression, with its patented platform. Backed by clinical data from multiple trials and an extensive patent portfolio, NeuroSigma aims to provide accessible, evidence-based neurotherapeutics.
View full company profileAbout NeuroSigma
NeuroSigma is a commercial-stage medical device company pioneering external trigeminal nerve stimulation (eTNS) for neuromodulation. Its flagship Monarch eTNS System holds FDA clearance for pediatric ADHD as a non-invasive, non-pharmacological treatment, representing a first-in-class device. The company is targeting large neurological markets, including epilepsy and depression, with its patented platform. Backed by clinical data from multiple trials and an extensive patent portfolio, NeuroSigma aims to provide accessible, evidence-based neurotherapeutics.
View full company profileTherapeutic Areas
Other Epilepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| ADX71149 (mGlu2 PAM) | Addex Therapeutics | Phase 2 |
| TRV045 | Trevena | Phase 1 |
| SAGE-324 | Sage Therapeutics | Preclinical |
| Motpoly XR™ | Aucta Pharmaceuticals | Not Specified (Likely Phase 3/NDA) |
| ADB-104 | Adolore BioTherapeutics | Pre-clinical |
| Not Publicly Disclosed | Cerecin | Phase 2 |
| NPT 2042 | NeuroPro Therapeutics | Phase 2 |
| Spritam (levetiracetam) | Aprecia Pharmaceuticals | Approved |
| Perampanel | Ark Diagnostics | In Development |
| NeuroAccess Platform | Cordance Medical | Pre-clinical/Research |
| Epilepsy Program | Current Surgical | Research |
| GABA-A PAM for Epilepsy | Modulate Bio | Preclinical |